Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) will release earnings results for the second quarter, before the opening bell on Friday, Aug. 1.
Analysts expect the Tarrytown, New York -based company to report quarterly earnings at $8.43 per share, down from $11.56 per share in the year-ago period. Regeneron Pharmaceuticals projects to report quarterly revenue at $3.28 billion, compared to $3.55 billion a year earlier, according to data from Benzinga Pro.
On July 2, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Regeneron’s Lynozyfic (linvoseltamab-gcpt) for adult patients with relapsed or refractory (R/R) multiple myeloma (MM) who have received at least four prior lines of therapy.
Regeneron Pharmaceuticals shares fell 1.6% to close at $545.46 on Thursday.
Benzinga readers can access the …